多伦多大学代写：18F的使用

多伦多大学代写：18F的使用

在医学上，实践发现，在使用18F-FDG PET/CT扫描的有效剂量(用于此目的)时，参与人群的相关终生癌症发病率约为0.514%。这些结果从个人和公共卫生的角度来看都很重要(Huang et al.， 2009)。在不同的参与人群中，诱发癌症的风险会有所不同。在同样的研究中，对来自香港的年轻参与者进行的研究似乎表明风险百分比增加了0.6%。因此，在使用18F的PET/CT扫描导致暴露的情况下，在进行扫描之前，有必要权衡风险与收益比(Huang et al.， 2009)。在处理核苷酸时，为了安全起见，必须维持所有一般程序。

多伦多大学代写：18F的使用
此外，18F在使用中也受到FDA的严格监管。用于诊断成像的药物于2000年3月10日被FDA批准。此外，还拟订了关于其使用的指导草案。因此，作为药品制造商的公司必须经过严格的合规措施，证明药品符合质量标准。评估的目的主要用于评价恶性肿瘤的葡萄糖代谢异常和利用在左心室功能障碍的评估,对于那些情况确定癫痫发作的焦点,该公司投资的持续生产药物必须严格遵守。

多伦多大学代写：18F的使用

In medical, practice is found that in the use of effective dose (which is required for the purpose) of the 18F-FDG PET/CT scanning, associated lifetime cancer incidence was around 0.514% for a participant population. The results are important from both an individual and a public health perspective (Huang et al., 2009). The induced cancer risks will differ among different participant segments. For the same study that conducted with participants from Hong Kong who were younger seems to indicate an increased risk percentage at 0.6 percent. So in the context of exposure due to a PET/CT scan using 18F, it is necessary to weigh the risk versus benefit ration before the scan is conducted (Huang et al., 2009). All general procedures have to be maintained in order to be safe while handling the nucleotide.

多伦多大学代写：18F的使用
18F in its use furthermore has been carefully regulated for by the FDA. The drug made use of in diagnostic imaging was cleared as of March 10, 2000 by the FDA. Draft guidance for its use was also developed as well. The company as the manufacturers of the drug hence would have to undergo stringent compliance measures that show, the drug meets quality standards. Used primarily for the purpose of assessing the abnormal glucose metabolism in evaluation of malignancy and made use of in left ventricular dysfunction assessment, and for those cases where the foci of epileptic seizures are to be identified, the company in investing for the continued manufacture of the drug has to show strict compliance.